Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Bio Green Med Solution

Request full access

Clinical-stage biopharma developing cell cycle cancer therapies

Kuala Lumpur, MalaysiaFounded 1996Biotech & Life Sciences

About Bio Green Med Solution

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on developing targeted drugs to treat cancer and other proliferative diseases by acting on the cell cycle. The company was founded in 1996 by Sir David Lane, who is renowned for discovering the p53 tumor suppressor protein, along with Professor Ian Kerr and institutional partners. Professor David Glover, a key figure in understanding cell division who discovered Polo and Aurora kinases, joined the firm in 1999. Initially established in the UK, Cyclacel later moved its headquarters to the United States to access capital markets and the pharmaceutical industry, eventually going public through a reverse merger with Xcyte Therapies in 2005.

Cyclacel's business model is centered on intensive research and development to create a diversified portfolio of novel drug candidates that address unmet medical needs in oncology and hematology. The company's revenue is primarily generated through collaborations and R&D activities, as it advances its pipeline through rigorous clinical trials to evaluate safety and efficacy. The company's strategy involves advancing its oncology programs internally before seeking partnerships to maximize commercial returns.

The company's pipeline is built on its expertise in cell cycle biology, transcriptional regulation, and mitosis. Key clinical-stage product candidates include Fadraciclib (CYC065), an orally available inhibitor of CDK2 and CDK9, and Plogosertib (CYC140), a selective PLK1 inhibitor. These candidates are being evaluated in mid-stage clinical trials for treating solid tumors, lymphomas, and hematological malignancies. Cyclacel aims to overcome cancer's resistance mechanisms by suppressing them and reactivating the body's natural cell death processes. The company retains worldwide marketing rights for its prescription candidates.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2006

Bio Green Med Solution in the Kuala Lumpur ecosystem

Live from Dealroom

The Bio Green Med Solution office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Excalibur Fund Managers

Series B and later2 investors entered at this stage

  • Scottish Equity Partners
  • Acorn Bioventures
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Bio Green Med Solution on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.